KRAS and neoplasm: Evidence at that time from small single-arm studies in chemorefractory mCRC suggested that responses to treatment with cetuximab were confined to patients whose tumours did not harbour KRAS codon 12 or 13 (exon 2) mutations (Di Fiore et al, 2007; De Roock et al, 2008; Lievre et al, 2008).